| Literature DB >> 30214162 |
Hyun Jeong Kim1, Young-Mo Yang1, Eun Joo Choi1.
Abstract
BACKGROUND: A number of symptomatic patients tend to use over-the-counter (OTC) medications and prescription medications. OTC medications can be easily obtained in pharmacies for self-treatment, but using OTC medications is not always safe and beneficial for patients. The aims of this study were to examine the use patterns of OTC medications and assess patients' perspectives regarding the use of OTC medications in Korean patients with chronic diseases. PATIENTS AND METHODS: A descriptive, cross-sectional survey was carried out with Korean patients who visited the community pharmacy, located at the southern region of South Korea, during September 2015.Entities:
Keywords: Korea; chronic disease; community pharmacy; over-the-counter drugs; survey
Year: 2018 PMID: 30214162 PMCID: PMC6118289 DOI: 10.2147/PPA.S173873
Source DB: PubMed Journal: Patient Prefer Adherence ISSN: 1177-889X Impact factor: 2.711
Figure 1Flow diagram of steps in the selection of study subjects.
Participant demographic and clinical characteristics
| Characteristics | Total, n (%) |
|---|---|
| Gender | |
| Male | 152 (44.1) |
| Female | 193 (55.9) |
| Age (years), mean ± SD | 61.4±12.3 |
| <45 | 21 (6.1) |
| 45–54 | 95 (27.5) |
| 55–64 | 97 (28.1) |
| 65–74 | 74 (21.4) |
| ≥75 | 58 (16.8) |
| Types of insurance | |
| National health insurance | 315 (91.3) |
| National medical aid | 29 (8.4) |
| Industrial accident compensation insurance | 0 (0.0) |
| Car insurance | 0 (0.0) |
| Others | 1 (0.3) |
| Number of prescription medications taken by participants, mean ± SD | 3.7±2.2 |
| ≤1 | 27 (7.8) |
| 2–4 | 228 (66.1) |
| 5–9 | 79 (22.9) |
| ≥10 | 11 (3.2) |
| Ten most frequently diagnosed chronic diseases in participants | |
| Hypertension | 282 (81.7) |
| Diabetes mellitus | 104 (30.1) |
| Hyperlipidemia | 97 (28.1) |
| Gastroduodenitis | 40 (11.6) |
| Gonarthrosis | 11 (3.2) |
| Menopausal disorders | 11 (3.2) |
| Heart failure | 10 (2.9) |
| Gastroesophageal reflux disease | 8 (2.3) |
| Dyspepsia | 8 (2.3) |
| Muscle tension | 8 (2.3) |
Participant demographic and clinical characteristics according to the use of OTC medications
| Characteristics | OTC medication user, n (%) (n=224) | OTC medication non-user, n (%) (n=121) | |
|---|---|---|---|
| Gender | |||
| Male | 107 (47.8) | 45 (37.2) | 0.058 |
| Female | 117 (52.2) | 76 (62.8) | |
| Age (years) | |||
| <65 | 149 (66.5) | 64 (52.9) | 0.012 |
| ≥65 | 75 (33.5) | 57 (47.1) | |
| Number of prescription medications taken by participants | |||
| ≤1 | 19 (8.5) | 8 (6.5) | 0.445 |
| 2–4 | 146 (65.2) | 82 (67.8) | |
| 5–9 | 54 (24.1) | 25 (20.7) | |
| ≥10 | 5 (2.2) | 6 (5.0) | |
| Chronic disease | |||
| Hypertension | 183 (81.7) | 99 (81.8) | 0.978 |
| Diabetes mellitus | 62 (27.7) | 42 (34.7) | 0.174 |
| Hyperlipidemia | 60 (26.8) | 37 (30.6) | 0.455 |
| Gastroduodenitis | 23 (10.3) | 17 (14.0) | 0.295 |
| Gonarthrosis | 6 (2.7) | 5 (4.1) | 0.463 |
| Menopausal disorders | 8 (3.6) | 3 (2.5) | 0.582 |
| Heart failure | 3 (1.3) | 7 (5.8) | 0.019 |
| Gastroesophageal reflux disease | 4 (1.8) | 4 (3.3) | 0.371 |
| Dyspepsia | 2 (0.9) | 6 (5.0) | 0.017 |
| Muscle tension | 4 (1.8) | 4 (3.3) | 0.371 |
Note:
Chi-squared test or Fisher’s exact test.
Abbreviation: OTC, over-the-counter.
Prevalence and patterns of chronic diseases according to gender and age
| Chronic diseases | Total, n (%) | Gender
| Age
| ||||
|---|---|---|---|---|---|---|---|
| Male, n (%) | Female, n (%) | <65 years, n (%) | ≥65 years n (%) | ||||
| Hypertension | 282 (81.7) | 121 (79.6) | 161 (83.4) | 0.363 | 166 (77.9) | 116 (87.9) | 0.020 |
| Diabetes mellitus | 104 (30.1) | 47 (30.9) | 57 (29.5) | 0.780 | 61 (28.6) | 43 (32.6) | 0.439 |
| Hyperlipidemia | 97 (28.1) | 37 (24.3) | 60 (31.1) | 0.166 | 58 (27.2) | 39 (29.5) | 0.642 |
| Gastroduodenitis | 40 (11.6) | 14 (9.2) | 26 (13.5) | 0.220 | 15 (7.0) | 25 (18.9) | 0.001 |
| Gonarthrosis | 11 (3.2) | 0 (0.0) | 11 (5.7) | 0.003 | 2 (0.9) | 9 (6.8) | 0.003 |
| Menopausal disorders | 11 (3.2) | – | 11 (5.7) | – | 10 (4.7) | 1 (0.8) | 0.043 |
| Heart failure | 10 (2.9) | 4 (2.6) | 6 (3.1) | 0.793 | 1 (0.5) | 9 (6.8) | 0.001 |
| Gastroesophageal reflux disease | 8 (2.3) | 4 (2.6) | 4 (2.1) | 0.732 | 2 (0.9) | 6 (4.5) | 0.031 |
| Dyspepsia | 8 (2.3) | 3 (2.0) | 5 (2.6) | 0.706 | 3 (1.4) | 5 (3.8) | 0.154 |
| Muscle tension | 8 (2.3) | 4 (2.6) | 4 (2.1) | 0.732 | 1 (0.5) | 7 (5.3) | 0.004 |
Note:
Chi-squared test or Fisher’s exact test.
Participants’ OTC medication use patterns according to gender and age
| OTC medication class | Total, n (%) | Gender
| Age
| ||||
|---|---|---|---|---|---|---|---|
| Male, n (%) | Female, n (%) | <65 years, n (%) | ≥65 years n (%) | ||||
| Antipyretics, analgesics and anti-inflammatory drugs | 150 (43.5) | 66 (43.4) | 84 (43.5) | 0.985 | 105 (49.3) | 45 (34.1) | 0.006 |
| Antihistamines | 89 (25.8) | 45 (29.6) | 44 (22.8) | 0.151 | 67 (31.5) | 22 (16.7) | 0.002 |
| Digestives | 62 (18.0) | 31 (20.4) | 31 (16.1) | 0.298 | 40 (18.8) | 22 (16.7) | 0.619 |
| Antitussives and expectorants | 47 (13.6) | 29 (19.1) | 18 (9.3) | 0.009 | 37 (17.4) | 10 (7.6) | 0.010 |
| Antacids | 33 (9.6) | 20 (13.2) | 13 (6.7) | 0.044 | 25 (11.7) | 8 (6.1) | 0.081 |
| Antiemetics | 28 (8.1) | 7 (4.6) | 21 (10.9) | 0.034 | 17 (8.0) | 11 (8.3) | 0.907 |
| Multivitamins | 26 (7.5) | 11 (7.2) | 15 (7.8) | 0.852 | 13 (6.1) | 13 (9.8) | 0.200 |
| Drugs for intestinal disorders | 17 (4.9) | 8 (5.3) | 9 (4.7) | 0.798 | 14 (6.6) | 3 (2.3) | 0.079 |
| Antispasmodics | 17 (4.9) | 8 (5.3) | 9 (4.7) | 0.798 | 14 (6.6) | 3 (2.3) | 0.079 |
| Drugs for peptic ulcer | 12 (3.5) | 6 (3.9) | 6 (3.1) | 0.673 | 8 (3.8) | 4 (3.0) | 1.000 |
| Laxatives and enemas | 7 (2.0) | 2 (1.3) | 5 (2.6) | 0.472 | 6 (2.8) | 1 (0.8) | 0.258 |
| Skeletal muscle relaxants | 6 (1.7) | 5 (3.3) | 1 (0.5) | 0.091 | 5 (2.3) | 1 (0.8) | 0.413 |
| Contraceptives | 4 (1.2) | – | 4 (2.1) | – | 4 (1.9) | – | – |
Note:
Chi-squared test or Fisher’s exact test.
Abbreviation: OTC, over-the-counter.
Participants’ perspectives toward OTC medication use according to gender and age
| Total, n (%) | Gender
| Age
| |||||
|---|---|---|---|---|---|---|---|
| Male, n (%) | Female, n (%) | <65 years, n (%) | ≥65 years n (%) | ||||
| Q1. What is your reason for using an OTC drug? | |||||||
| Pain | 67 (19.4) | 43 (28.3) | 24 (12.4) | <0.001 | 54 (25.4) | 13 (9.8) | <0.001 |
| Cold | 97 (28.1) | 40 (26.3) | 57 (29.5) | 0.509 | 67 (31.5) | 30 (22.7) | 0.080 |
| Dyspepsia | 78 (22.6) | 37 (24.3) | 41 (21.2) | 0.495 | 49 (23.0) | 29 (22.0) | 0.823 |
| Heartburn | 34 (9.9) | 19 (12.5) | 15 (7.8) | 0.144 | 23 (10.8) | 11 (8.3) | 0.455 |
| Fatigue | 28 (8.1) | 14 (9.2) | 14 (7.3) | 0.509 | 19 (8.9) | 9 (6.8) | 0.487 |
| Diarrhea | 6 (1.7) | 1 (0.7) | 5 (2.6) | 0.235 | 5 (2.3) | 1 (0.8) | 0.413 |
| Constipation | 17 (4.9) | 8 (5.3) | 9 (4.7) | 0.798 | 14 (6.6) | 3 (2.3) | 0.079 |
| Others | 48 (13.9) | 20 (13.2) | 28 (14.5) | 0.719 | 23 (10.8) | 25 (18.9) | 0.034 |
| Q2. How often had you used an OTC drug within the last 30 days? | |||||||
| <6 | 285 (82.6) | 129 (84.9) | 156 (80.8) | 0.326 | 190 (89.2) | 95 (72.0) | <0.001 |
| ≥6 | 60 (17.4) | 23 (15.1) | 37 (19.2) | 23 (10.8) | 37 (28.0) | ||
| Q3. Do you think that an OTC drug is effective? | |||||||
| Mean ± SD | 3.9±0.9 | 4.0±1.0 | 3.9±0.9 | 0.573 | 3.9±0.9 | 3.9±1.0 | 0.754 |
| Q4. Do you think that pharmacists’ medication counseling is necessary when purchasing an OTC drug? | |||||||
| Mean ± SD | 4.0±1.1 | 4.0±1.2 | 4.0±1.0 | 0.978 | 4.0±1.1 | 4.0±1.0 | 0.840 |
| Q5. Do you give pharmacists information on drugs which you currently take when purchasing an OT C drug? | |||||||
| Mean ± SD | 3.6±1.4 | 3.6±1.4 | 3.6±1.4 | 0.879 | 3.6±1.4 | 3.7±1.3 | 0.620 |
| Q6. Do you know that an OTC drug can cause adverse reactions or interact with prescription drugs which you currently take? | |||||||
| Mean ± SD | 2.7±1.3 | 2.7±1.4 | 2.7±1.3 | 0.524 | 2.9±1.3 | 2.3±1.2 | <0.001 |
| Q7. Do you read the package leaflet of an OTC drug when using it? | |||||||
| Mean ± SD | 2.2±1.2 | 2.4±1.2 | 2.0±1.2 | 0.006 | 2.5±1.2 | 1.8±1.1 | <0.001 |
Notes:
Chi-squared test, Fisher’s exact test or independent t-test.
Rating scale: 5= strongly agree, 4= agree, 3= neutral, 2= disagree and 1= strongly disagree.
Rating scale: 4= strongly agree, 3= agree, 2= disagree and 1= strongly disagree.
Abbreviation: OTC, over-the-counter.
Drug–drug interactions between drugs that participants had taken
| Drugs | Interaction drug | Frequency of use | Severity | Quality of evidence | Summary |
|---|---|---|---|---|---|
| Aspirin | Thiazide | 6 | Major | Good | Reduced diuretic effectiveness and possible nephrotoxicity |
| Atenolol, bisoprolol, carvedilol | 6 | Moderate | Good | Decreased antihypertensive effect | |
| Meloxicam | 2 | Major | Fair | Increased risk of bleeding | |
| Ranitidine | 6 | Minor | Excellent | Decreased plasma levels of aspirin and its antiplatelet effect | |
| Al(OH)2, Mg(OH)2, MgO | 5 | Moderate | Fair | Decreased effectiveness of aspirin | |
|
| |||||
| Atenolol | Diltiazem | 1 | Major | Good | Increased risk of hypotension, bradycardia, AV conduction disturbances |
| Glimepiride, metformin | 3 | Moderate | Good | Hypoglycemia or hyperglycemia, decreased symptoms of hypoglycemia | |
| Al(OH)2, Mg(OH)2, CaCO3 | 4 | Minor | Good | Decreased effectiveness of atenolol | |
|
| |||||
| Belladonna | Chlorpheniramine | 1 | Minor | Fair | Excessive anticholinergic activity |
|
| |||||
| Caffeine | Alprazolam, lorazepam | 2 | Minor | Good | Decreased sedative and anxiolytic effects of alprazolam and lorazepam |
| Estradiol valerate, medroxyprogesterone | 2 | Moderate | Good | Enhanced central nervous system stimulation | |
|
| |||||
| Carvedilol | Metformin, sitagliptin | 2 | Moderate | Good | Hypoglycemia or hyperglycemia, decreased symptoms of hypoglycemia |
|
| |||||
| Cilostazol | 10 | Major | Good | Increased risk of bleeding | |
|
| |||||
| Diltiazem | Clopidogrel | 2 | Major | Excellent | Decreased antiplatelet effect and increased risk of thrombotic events |
| Ranitidine | 1 | Minor | Good | Increased diltiazem concentrations and possible cardiovascular toxicity | |
|
| |||||
| Fluconazole | Atorvastatin | 1 | Major | Fair | Increased risk of myopathy or rhabdomyolysis |
| Tamsulosin | 1 | Moderate | Fair | Increased exposure of tamsulosin | |
| Tramadol | 1 | Major | Fair | Increased tramadol exposure and risk of toxicity | |
|
| |||||
| Thiazide | 3 | Moderate | Good | Increased blood pressure | |
|
| |||||
| Glimepiride | Carvedilol, nebivolol | 2 | Moderate | Good | Hypoglycemia or hyperglycemia, decreased symptoms of hypoglycemia |
| Sitagliptin | 8 | Moderate | Fair | Increased risk of hypoglycemia | |
| Ranitidine | 1 | Moderate | Fair | Increased blood glucose-lowering effect and increased risk of hypoglycemia | |
| Thioctic acid | 4 | Major | Fair | Increased risk of hypoglycemia | |
|
| |||||
| Meloxicam | Angiotensin II receptor blockers | 3 | Moderate | Excellent | Renal dysfunction or decreased antihypertensive efficacy |
| Thiazide | 3 | Major | Good | Reduced diuretic effectiveness and possible nephrotoxicity | |
| Carvedilol | 1 | Moderate | Good | Decreased antihypertensive effect | |
|
| |||||
| Prednisolone | Thiazide | 1 | Moderate | Fair | Hypokalemia |
|
| |||||
| Rosuvastatin | Al(OH)2, Mg(OH)2 | 2 | Moderate | Fair | Decreased rosuvastatin effectiveness |
|
| |||||
| Thiazide | Ibuprofen | 1 | Major | Good | Reduced diuretic effectiveness and possible nephrotoxicity |
| CaCO3 | 1 | Moderate | Fair | Increased risk of hypercalcemia | |
|
| |||||
| Thioctic acid | Metformin, sitagliptin | 4 | Major | Fair | Increased risk of hypoglycemia |
|
| |||||
| Tramadol | Amitriptyline | 1 | Major | Fair | Increased risk of seizure, serotonin syndrome, opioid toxicity and increased levels of tramadol |
Notes:
Contraindicated – the drugs are contraindicated for concurrent use; major – the interaction may be life-threatening and/or need medical intervention to minimize or prevent serious adverse effects; moderate – the interaction may exacerbate the patient’s condition and/or need an alternative therapy; minor – the interaction may cause an increase in the frequency or severity of side effects but would not need a major alternative therapy.
Excellent – the existence of the interaction has clearly been established through controlled studies; good – the existence of the interaction is strongly suggested through documentation, but well-controlled studies are rare; fair – available documentation is poor, but pharmacologic concerns lead clinicians to suspect the existence of the interaction or documentation regarding pharmacologically similar drug is good.
Abbreviation: AV, atrioventricular.